论文部分内容阅读
Ⅲ期非小细胞肺癌(NSCLC)单纯放疗存活期中值为12个月,2年存活率10％～15％。化、放疗或化疗结合手术可提高存活率,但综合治疗中化疗以顺铂为主,该方案要求病人身体状况较高、较严。该研究中心有25％的Ⅲ期NSCLC病人不适合,因此本文探索性研究,以评估卡铂、足叶乙甙同时放射治疗这些具有较坏影响因素的Ⅲ期NSCLC病人的疗效、耐受性。
The median survival time for stage III non-small cell lung cancer (NSCLC) with radiotherapy alone is 12 months, and the 2-year survival rate is 10% to 15%. Chemotherapy, radiotherapy, or chemotherapy combined with surgery can improve the survival rate. However, in comprehensive treatment, chemotherapy is mainly cisplatin, which requires the patient to have a higher physical condition and stricter treatment. At the Center, 25% of patients with stage III NSCLC are unsuitable. Therefore, an exploratory study was conducted to evaluate the efficacy and tolerability of patients with stage III NSCLC with relatively influential factors, such as carboplatin and etoposide.